Descent from a single ancestor cell
POPULARITY
9 episodes with monoclonal
8 episodes with monoclonal
2 episodes with monoclonal
4 episodes with monoclonal
4 episodes with monoclonal
4 episodes with monoclonal
2 episodes with monoclonal
2 episodes with monoclonal
2 episodes with monoclonal
“A lot of other disease sites, they have some targeted therapies, they have some immunotherapies [IO]. In lung cancer, we have it all. We have chemo. We have IO. We have targeted therapies. We have bispecific T-cell engagers. We have orals, IVs. I think it's just so important now that, particularly for lung cancer, you have to be well versed on all of these,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 16, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer treatments. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episode: Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Lazertinib Oncology Drug Reference Sheet: Nivolumab and Hyaluronidase-Nvhy Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki Optimize Your Testing Strategy and Improve Patient Outcomes With NeoGenomics' Neo Comprehensive™–Solid Tumor Assay Clinical Journal of Oncology Nursing article: Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice Nurse ONS Biomarker Database ONS video: What is the role of the KRAS biomarker in NSCLC? Biomarker Testing in Non-Small Cell Lung Cancer Discussion Tool ONS Huddle Cards: Checkpoint inhibitors External beam radiation Monoclonal antibodies Proton therapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Unfortunately, because lung cancer is pretty aggressive, we'll see lung cancer mostly in stage IV. So about 50%–55% of all cases are not caught until they are already metastatic, or stage IV. And then about another 25%–30% of cases are caught in stage III, which means they're locally advanced and often not resectable, but we do still treat that with curative intent with concurrent chemoradiation. And then 10%–20% of cases are found in the early stage, and that's stage I and II, where we can do surgical approaches.” TS 2:53 “The majority of radiation that you're going to see is for patients with stage III disease that's inoperable. At my institution, a lot of stage III is inoperable. Now, neoadjuvant immunotherapy has changed that a little bit. But if you have several big, bulky, mediastinal lymph nodes that makes you stage III, surgery is probably not going to be a great option. So we give curative-intent chemoradiation to these patients.” TS 10:51 “Oligoprogression would mean they have metastases but only to one site. And sometimes we will be aggressive with that. Particularly, there's good data, if the only site of progression is in the brain, we can do stereotactic radiation to the brain and then treat the chest with concurrent chemoradiation as a more definitive approach. But outside of that, the majority of stage IV lung cancer is going to be treated with systemic therapy.” TS 15:00 “It's important for nurses to know that there's a lot of different options now for treatment. Probably one of the most important things is making sure patients are aware of what their biomarker status is, what their PD-L1 expression level is, and make sure those tests have been done. … It's good that the patients understand that there's a myriad of options. And a lot of that depends on what we know about their cancer, and then that guides our treatment.” TS 31:05
A study in NEJM shows that abelacimab, a fully human monoclonal antibody targeting factor XI, significantly reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients, suggesting a safer alternative for stroke prevention. Data from JAMA Health Forum reveals growing consolidation of primary care practices by hospitals and private equity firms, driving up healthcare costs without clear quality improvements. The largest U.S. tuberculosis outbreak in Kansas underscores the importance of vigilance and rapid response by healthcare providers, while a study in JAMA Network Open finds women, particularly nonmenopausal females aged 40–54, at higher risk for long COVID, emphasizing the need for tailored prevention and treatment strategies.
BUFFALO, NY - December 11, 2024 – A #news feature on the #research paper “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition” by Rackear et al. was #published in Oncotarget's Volume 15 on November 22, 2024, titled “Advancements in cell-penetrating monoclonal antibody treatment." This new publication by Sai Pallavi Pradeep and Raman Bahal from the Department of Pharmaceutical Sciences at the University of Connecticut highlights significant advancements in monoclonal antibody (mAb) therapies. The focus is on the 3E10 antibody, originally derived from autoimmune mouse studies in systemic lupus erythematosus. Unlike traditional mAbs, which struggle to reach intracellular targets, this cell-penetrating antibody targets cancer cells by addressing a major limitation of current therapies. By targeting RAD51, a key intracellular protein involved in DNA repair, the 3E10 antibody shows great promise for cancer treatment, particularly in cancers with defective DNA repair pathways. mAbs have already changed the landscape of cancer therapy, offering treatments that are more targeted and have fewer side effects compared to chemotherapy. However, current therapies are limited since mAbs only target proteins on the surface of cancer cells. This research pushes the boundaries by demonstrating how 3E10 antibodies can penetrate cells and access their internal molecules. This unique capability expands the potential of mAb therapies and targeted cancer treatments. Different humanized versions of the 3E10 antibody were created and carefully tested. Some versions were particularly effective at blocking RAD51, while others showed promise for carrying other therapeutic molecules like genetic material into the cancer cells. This flexibility means that 3E10 could be used to treat different cancer types and deliver various therapeutic molecules directly into tumor cells. This progress offers exciting new possibilities for treating cancer tumors that are resistant to conventional therapies. In conclusion, the 3E10 antibody's dual function—targeting DNA repair pathways and delivering therapeutic molecules—positions it as a transformative tool in cancer research and targeted cancer treatments. DOI - https://doi.org/10.18632/oncotarget.28674 Correspondence to - Raman Bahal - raman.bahal@uconn.edu Video short - https://www.youtube.com/watch?v=3uMdPvThFHA Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28674 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ Keywords - cancer, monoclonal anti-bodies, cell penetration, nucleic acid delivery, 3E10 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
In the second installment of this two-part series, Dr. Tesha Monteith and Dr. Messoud Ashina discuss the results of the phase two study on monoclonal antibody to PACAP for migraine prevention. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2314577
In the first installment of this two-part series, Dr. Tesha Monteith and Dr. Messoud Ashina explore the biology of PACAP, its significance in relation to migraines, and its potential as a novel therapeutic approach. Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2314577
Dr. Tesha Monteith talks with Dr. Messoud Ashina about the biology of PACAP, its significance in relation to migraines, and its potential as a novel therapeutic approach. Read the related article in The New England Journal of Medicine. Disclosures can be found at Neurology.org.
Natalie from the US shares her Eds (hypermobile syndrome), pots, monoclonal mast disease experience with us.
In this episode, we review the high-yield topic of Monoclonal Gammopathy of Undetermined Significance (MGUS) from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Monoclonal antibodies are used to treat cancer. Or is it asthma? Skin conditions? Wait, didn't we use those for covid, too?? The answer is yes! Jody reviews the basic mechanism of these versatile medications as well as their naming conventions and a bit about how they are discovered. References: 1) Manis, J. Overview of therapeutic monoclonal antibodies. UpToDate. 2) Mayo Clinic Staff. Monoclonal antibody drugs for cancer: How they work. Retrieved from https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808
In this week's episode, we'll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and immunogenetic signatures can be used in the prediction of outcomes for high-count monoclonal B lymphocytosis.Featured Articles: Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: The HUNT study
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.(00:32) Do you mind giving the audience more information about yourself and your background? (01:53) Could you please give a brief overview of this assay? (03:35) Which patients should have this testing and when should it be performed? (04:57) How are the results used in patient care? (06:59) Other monoclonal antibody therapies are usually monitored by a combination of drug quantification and analysis of antidrug antibodies. How is this test being offered?
According to the results of a recent study, researchers have found a treatment that completely removed the rectal cancer in every patient that participated. Meaning that every single patient in the study is in remission—and with no chemotherapy, no radiation, and no surgery. Even though the study was small, the results are not only heartening, but also, according to the lead researcher, they open up a potential new corridor at fighting cancer, which they will be expanding quickly to stomach, pancreatic, and bladder cancer.
News
News
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the... The post Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception appeared first on VJHemOnc.
Monoclonal antibodies for Alzheimer's disease, like the drug called Aduhelm, attach to aberrant proteins thought to be one cause of the disease, but they only stand to benefit a small number of the people who might be at risk. That's … Only a small percentage of people are candidates for monoclonal antibodies to treat Alzheimer's disease, Elizabeth Tracey reports Read More »
Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions: Bri: Hello, I have a friend who was recently diagnosed with MGUS (monoclonal gammopathy) a condition in which an atypical protein is found in the blood and you have a increased risk of having cancer in the future. If this were you, what would you do? Or what path would you start looking down? Alicia: A holistic chiropractor informed us that our 6 year old son has a hiatal hernia. His symptom is a cough at night after he's been asleep about an hour that eventually progresses to him throwing up. After that he's able to return to sleep. This used to happen a few times a year and now it's just been once so far this winter. Please explain what a hiatal hernia is, if it's common in children, and how we can help him. HC: Hello Dr. Cabral, Thank you for all you do for your community. I appreciate your selflessness and committment to inform us on real truths of healing!! Do you any knowledge on antioxidant Carbon 60? I have been looking at product (Carbon360) and would appreaciate your feedback. THank you again for all you do!!!! Heather: Hey doc! Thanks as always for taking the time to answer our questions. Could you talk more in-depth about Beau's lines (the horizontal dents in nails that make them look warp-liked)? I listened to your podcasts on nails and you briefly mentioned these lines mean digestive-based issues. I've gone through the CBO Protocol & Gut Finisher, did a Food Sensitivity test & confirmed I only have a moderate sensitivity to rye & miso. The Beau's lines weren't something I noticed until recently when they started appearing on my fingernails but now I realize I've had them on my toenails for quite some time, otherwise, I would have brought it up to my health coach at the time I was working through the CBO. Thanks again! Sienna: Hi doctor Cabral, I (47F) would love to do a 3-day water fast for health benefits, but without messing up my hormones and losing muscle. What would be the best way to approach this? Thanks so much for your answer! Sienna Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions! - - - Show Notes and Resources: StephenCabral.com/2955 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
Veterinary Advice, Animal News & Views with hosts, Dr. Roger Welton & Dr. Karen Louis
Arthritis is the most common chronic disease in dogs and cats. Arthritis in pets can be debilitating and commonly reaches levels of severity where quality of life diminishes to the point of humane euthanasia. In this episode, Dr. Roger discusses the latest cutting edge therapy for dogs and cats with arthritis that is not only restoring quality of life to arthritic pets, while significantly extending their life expectancy. Dr. Roger Welton is a practicing veterinarian and media personality, CEO/attending veterinarian at Premier Veterinary Care, and author of the top selling book, The Man In The White Coat. Dr. Roger selects listener emails to be addressed on the air, so if interested in having your voice heard on the podcast, email comments or questions to comments@web-dvm.net. For more content from Dr. Roger visit his blog at Web-DVM.net and you can also follow his public Facebook profile by friend requesting "Roger Welton DVM".
Since the onset of canine parvovirus in the 1970s, we've made great strides with vaccination. That being said, unfortunately, we still see canine parvovirus cases. Join Dr. Meghan Herron, DVM, DACVB, to learn about an exciting treatment option that is available! Brought to you by our friends at Elanco: https://www.elanco.com/en-us
On this episode of TWiV we discuss unusual properties of monoclonal antibodies: one that that binds the receptor attachment site and blocks infection with all three poliovirus serotypes, and others that inhibit Ebolavirus spread from cell to cell. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Angela Mingarelli Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Global Scholar Travel Awards (ASV) Research assistant position in Rosenfeld Lab CBER/FDA (pdf) Monoclonal antibody neutralizes all three poliovirus serotypes (Nat Comm) Blocking Ebolavirus intercellular spread (Cell Rep) Letters read on TWiV 1059 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Climate Science Angela – Spider Ballooning (Wikipedia) Kathy – Richard Harris Art Collection Rich – “The Murderbot Diaries” by Martha Wells Alan – Old Gods of Appalachia Vincent – Poetry Foundation Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked.
In the first ever podcast collaboration between ISN and ASON; Raad Chowdhury hosts a panel of Fellows in discussing an Onconephrology Case with an electrolyte twist.
In recent months the FDA and CDC approved two new drugs that experts say will change how respiratory syncytial virus (RSV) is managed. This comes at a critical time, says Mundeep Kainth, DO, MPH, as hospitals prepare for the influx of RSV, flu and Covid cases this fall and winter. The convergence of those three respiratory viruses, termed a "tripledemic," overwhelmed hospitals nationally last winter. Dr. Kainth, a pediatric infectious disease expert at Cohen Children's Medical Center, says these two new protections, just like the flu shot and Covid-19 vaccines, are critical tools to help prevent serious illness and keep people out of the hospital. On this episode, she explains what everyone should know about the first-ever RSV vaccine, which is for pregnant mothers between 32 and 36 weeks, and those older than 60, as well as the new monoclonal antibody nirsevimab (brand name Beyfortus), which is for newborns.
Michael Peluso M.D., an HIV and infectious disease specialist at UCSF, has been studying Long Covid patients since April 2020 (LIINC Study). This, along with his history of working with HIV and other viruses, has given him the knowledge and methods to make some break-throughs into Long Covid pathogenesis, effects and, potentially, treatments. He, along with his team, has established that Long Covid causes T-cell and immune dysregulation and he has used multimodal molecular imaging to reveal that viral RNA reservoirs are persistent in Long Covid patients. With the aim of clearing this viral debris, Peluso is now leading a clinical trial using a monoclonal antibody infusion.Living with Long Covid? How was your week?Website - https://www.tlcsessions.net/Twitter - @SessionsTlc https://twitter.com/sessionstlcInsta - @tlcsessions https://www.instagram.com/tlcsessions
In this week's episode, we discuss real-world evidence for CAR T cell therapy in older patients with diffuse large B-cell lymphoma, inhibiting endogenous anticoagulant pathways in congenital factor deficiencies, and finally targeting the HSP90 epichaperome in acute myeloid leukemia.
Pink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron's deal with the US government to develop a COVID-19 monoclonal antibody (:34), US FDA Commissioner Robert Califf hiring a new senior advisor (12:10), and optimizing dosing in cancer combination therapies (21:21). More On These Topics From The Pink Sheet Price Caps In Regeneron's COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie: https://pink.citeline.com/PS148843/Price-Caps-In-Regenerons-COVID-Monoclonal-Deal-With-HHS-Not-A-Precedent-But-Enough-For-Bernie Califf Hires New US FDA Senior Advisor, But Duties Seem Vague: https://pink.citeline.com/PS148848/Califf-Hires-New-US-FDA-Senior-Advisor-But-Duties-Seem-Vague Project Optimus Is Coming To Cancer Combination Therapy Development: https://pink.citeline.com/PS148841/Project-Optimus-Is-Coming-To-Cancer-Combination-Therapy-Development
Title: New RSV Monoclonal Antibody and Vaccine Conversation Target Audience This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards. Objectives: Upon completion of this activity, participants should be able to: Review how monoclonal antibodies work in fightin disease. Review Nirsevimab and the ACIP and AAP reccomendations for its use. Discuss how monoclonal antibodies are different from vaccines and discuss the new RSV vaccines being released. Faculty: Planning Committee: Maha Kaissi, MD, MHPE — Assistant Professor of Pediatrics, Division of Pediatric Hospital Medicine, UPMC Children's Hospital of Pittsburgh Course Directors: Tony R. Tarchichi MD — Assistant Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine Dr. Tarchichi has disclosed he was a member of the Advisory Board for meningococcal vaccine in immunocompromised patient for Sanofi Corp John Williams, MD — Professor in the Dept. of Pediatrics at the University of Pittsburgh, Division Director for Pediatric Infectious Disease Division at University of Pittsburgh Medical Center (UPMC). Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity. Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Released 8/29/2023, Expires 8/29/2026 The direct link to the course is provided below: COMING SOON!!
Dr. Eugene Chan, Chairman and Co-Founder of Abpro, talks about the next generation of antibody therapies that can target more than one target to activate the immune system in the fight against cancer. Abpro is also working on a prophylactic antibody therapy to help prevent immunocompromised patients from getting COVID. Eugene explains, "Abpro has developed the antibodies, in a lot of these cases, to be able to target more than one target. This basically activates the immune system more so that whatever you're targeting is cleared more rapidly from the body. This applies to the cases of cancer that we are focused on, and we've basically developed these antibodies called bispecific antibodies - bi for targeting two different sites. These antibodies essentially have more and greater activity than conventional antibodies." "We developed a program and antibodies that bind to HER2+, which is one of the molecular markers on breast and gastric cancers. This particular therapy brings the immune system, the body's own natural immune system, to these cancer cells in a very active manner, which then allows it to get cleared from the body much sooner than the other mono-specific therapies that are currently out there." "Monoclonal antibodies are the body's own natural defense system for a lot of diseases. The ability to take these and augment and make them better is really the way to go because, ultimately, the body is already accustomed to these types of molecules. So we know to some degree they're safe. When compared to things like chemotherapy or even radiotherapy, these things are going to be much safer because they naturally exist in some way, shape or form in the body when you're fighting a disease or when your body's exposed to a new antigen or some sort of new threat. We're taking this approach and enhancing the body's ability to fight cancer and infection by augmenting the structure of these molecules." #Abpro #Antibodies #MonoclonalAntibodies #Cancer #Tumors #COVID #HER2+ abpro.com Download the transcript here
Dr. Eugene Chan, Chairman and Co-Founder of Abpro, talks about the next generation of antibody therapies that can target more than one target to activate the immune system in the fight against cancer. Abpro is also working on a prophylactic antibody therapy to help prevent immunocompromised patients from getting COVID. Eugene explains, "Abpro has developed the antibodies, in a lot of these cases, to be able to target more than one target. This basically activates the immune system more so that whatever you're targeting is cleared more rapidly from the body. This applies to the cases of cancer that we are focused on, and we've basically developed these antibodies called bispecific antibodies - bi for targeting two different sites. These antibodies essentially have more and greater activity than conventional antibodies." "We developed a program and antibodies that bind to HER2+, which is one of the molecular markers on breast and gastric cancers. This particular therapy brings the immune system, the body's own natural immune system, to these cancer cells in a very active manner, which then allows it to get cleared from the body much sooner than the other mono-specific therapies that are currently out there." "Monoclonal antibodies are the body's own natural defense system for a lot of diseases. The ability to take these and augment and make them better is really the way to go because, ultimately, the body is already accustomed to these types of molecules. So we know to some degree they're safe. When compared to things like chemotherapy or even radiotherapy, these things are going to be much safer because they naturally exist in some way, shape or form in the body when you're fighting a disease or when your body's exposed to a new antigen or some sort of new threat. We're taking this approach and enhancing the body's ability to fight cancer and infection by augmenting the structure of these molecules." #Abpro #Antibodies #MonoclonalAntibodies #Cancer #Tumors #COVID #HER2+ abpro.com Listen to the podcast here
Sandra Mazzoni, DO, a hematologist at Cleveland Clinic Taussig Cancer Institute joins the Cancer Advances podcast to talk about monoclonal gammopathy of undetermined significance, known as MGUS. Listen as Dr. Mazzoni talks about this abnormal protein and explains when we can still effectively treat patients before it hits all the criteria for becoming multiple myeloma.
This is a LIVE replay (edits made due to technical difficulties) of A Trauma Survivor Thriver's Podcast which aired Wednesday, May 17th, 2023 at 1130am ET on Fireside Chat. Today's guest is Noga Schechter, Mental Health and Disordered Eating Advocate. Lorilee Binstock 00:00:28 Welcome. I'm Lorilee Binstock, and this is A Trauma Survivor Thriver's Podcast. Thank you so much for joining me live on Fireside where you can be a part of the conversation as my virtual audience. I am your host, Laura Lee Benstock. Everyone has an opportunity to ask me or our guest questions by requesting to hop on stage or I'm sending a message in the chat box. I will try to get you, but I do ask that you'd be respectful. Today's guest is Noga Schecther, Mental Health and Disordered Eating Advocate. Noga, thank you so much for joining me today. Noga Schechter 00:01:20 Oh my gosh. Thank you for having me. I remember how I found you. Lorilee Binstock 00:01:25 How did you find me? Noga Schechter 00:01:27 I was just looking for an avenue to to talk about these things, and I couldn't believe how they're just isn't that much out there. And you were in really easy find because there just aren't as many dedicated Lorilee Binstock 00:01:37 Yep. Noga Schechter 00:01:43 places where you can start talking about these types of issues as much as one would think. So I was really excited to find you. Lorilee Binstock 00:01:49 Ma'am, Oh, well, thank you. And I appreciate, you know, we've had conversations before, and you actually you shared with me, even before we got on our phone call about Noga Schechter 00:01:59 Yeah. Lorilee Binstock 00:01:59 your your childhood trauma, which really Noga Schechter 00:02:02 Yeah. Lorilee Binstock 00:02:03 seem to extend until adulthood. Would you mind sharing that? Noga Schechter 00:02:10 Yeah. I I think, you know, I grew up For starters, an immigrant from Israel, I I I came here to the US when I was six. And I grew up in an environment where there wasn't necessarily a safe place. My mom was very traumatized from her own childhood. She suffered from alcoholism, and lots of mental health issues. My father, I think, at the time, was just trying to keep everything together as the glue of the family. So he was So he was just really inundated with with crisis management. So As a as a as a young girl, I I I was just always on my own. You know? And and that, you know, when you're when you're a child, you don't know how to process things, especially pain. Or discomfort or just truth. And so I went about processing I I went about most of my childhood with an inability to process the trauma that I that I have in third. Lorilee Binstock 00:03:29 I know you said your dad dealt with a lot of Christ management, was he able Noga Schechter 00:03:33 Again. Lorilee Binstock 00:03:34 to comfort you? Did you did you feel comfortable sharing any issues or pain you know, children children need to share. And so we're Was was he able to do that, or was it just, like, so overwhelming by just managing what he had to already manage? Noga Schechter 00:03:45 Yeah. Yeah. No. Yeah. No. I was alone. I mean, I didn't have any comfort in my We had don't get me wrong. I mean, we had fun moments as a family. We took vacations. But in the day to day, from when I can even remember, I was processing alone. I was learning alone. I was processing alone. I was dealing alone, I did not have a comfortable space to go to go talk ever, ever. Until I reached you on the adulthood. Yeah. Lorilee Binstock 00:04:27 Wow. So and and, you know, not having a person there for you. Especially as a child, that cat that is trauma. Noga Schechter 00:04:33 Yeah. Lorilee Binstock 00:04:36 There's trauma. When you have when when you're learning how to cope with something, Noga Schechter 00:04:36 Yeah. Lorilee Binstock 00:04:42 then you can't turn to an adult, that that must have been really hard. Noga Schechter 00:04:47 Well, you know, you don't really know. I mean, you know that it's hard I knew it was hard. I knew I was in pain, but I thought that that was normal. Yeah. I I didn't really understand how damaging my household was until the shoe dropped is what I call it. You know? With young adult where you're looking around at your life, you know, in your mid twenties and you're like, why is everything wrong? You know, So it's you know, I use this word a lot right now. It's I use the word egoic construct. Right? So I I I was in an ego contract thinking that this was okay, this was normal, and this is whatever how everyone lived. Lorilee Binstock 00:05:32 Mhmm. Noga Schechter 00:05:33 Not having support being alone, you know, which caused a a huge habit for magical thinking is what I call. What I call it, Lorilee Binstock 00:05:44 Yeah. Noga Schechter 00:05:44 you know, I went into years and years of magical thinking, which is, you know, we call it being a dreamer as adults. But when you're a child and you don't have the ability to process your trauma, you start hoping and wishing hoping and wishing all the time, and that's how one processes. And you think the hoping and wishing hoping and wishing is going to change your environment and change your situations, but we know that that's not the case. Right? It's it's with incremental actions that life changes. So, you know, there were some habits that I picked up from essentially being alone, and that I took into a thought that that became extremely unhealthy. Lorilee Binstock 00:06:31 When was it that you began to you said in your twenties, you started using did you start I know we were talking about trauma and disordered eating, Noga Schechter 00:06:40 Yeah. Yeah. Yeah. Lorilee Binstock 00:06:43 was when did you start using food to help you cope? Noga Schechter 00:06:47 You know, I think I always did. You know? Like, I think I always did I think what I think it was really around puberty, like, around twelve or thirteen where I started really eating a lot way beyond peeling full. And but I have to be honest, it's just been a blur ever since because when you're in that state, you know, this this this crisis, this constant crisis, constant coming. It's hard to remember a lot of it. It feels like it's just so much of a blur. Lorilee Binstock 00:07:24 Right. Noga Schechter 00:07:25 But but, specifically, when I was in my mid twenties, I was married. I I married really young. Basically, a replica of my mother, you know, a big drinker, a big gambler, irresponsible, not not reliable and damaging. Just a very damaging relationship. And that mimics my household. Right? Because that's what you do. Lorilee Binstock 00:07:54 Right. Right. Noga Schechter 00:07:54 And and I remember those were the nights where I started to, like, eat myself to sleep. You know? Like like, though that's when the behavior started becoming. Lorilee Binstock 00:08:08 Mhmm. Noga Schechter 00:08:09 Past self harm into, like, I may be killing myself. Lorilee Binstock 00:08:14 Wow. Noga Schechter 00:08:16 And and and it's over time. Right? It doesn't happen. It it the body is a pro is is Lorilee Binstock 00:08:16 Mom. Noga Schechter 00:08:22 the human body is is a progression. It's a snapshot of a of a progression. Right? It's not it's not what it is right now, what you're doing right now. So over time, I was essentially almost killing myself. I was My hormones were totally out of whack because when I was eating, I I had gird. I I I I was pretty diabetic. I got up to three hundred and sixteen pounds. That was the heaviest. But Lorilee Binstock 00:08:50 Well, Noga Schechter 00:08:53 really, in young adulthood, like, my mid twenties into my late twenties is when I started self harming. And that was doing it past the point, like, eating past the point of full, past the point of over eating, and into the place of I hate myself, so I'm going to eat until I'm tired and I go to sleep. So Lorilee Binstock 00:09:18 You know, he yeah. Go ahead. Noga Schechter 00:09:21 yeah. That's I mean, that's where I that's where I initially got. And I knew everything was wrong. I I didn't know how happy I was. I you know you look in the mirror, but I didn't I didn't fully understand what was going on. I it was still very much, so I was in a place of slight mania, crisis, pain. I couldn't see straight. I didn't know anything outside of that construct. Lorilee Binstock 00:09:52 You know, eating disorders, I feel like it can be really difficult because you said what stuck out to me was I think I think I always Noga Schechter 00:09:53 Yeah. Lorilee Binstock 00:10:01 was just using food as a coping mechanism. Noga Schechter 00:10:03 Yeah. Yeah. Lorilee Binstock 00:10:05 And it's hard because it's, like, you have to eat. You have it's not like drugs. Right? Like, it's not one of those things. Like, oh, you see someone doing cocaine. You know, that Noga Schechter 00:10:12 Yeah. Lorilee Binstock 00:10:15 we need to do something. Like, you see someone eating and you don't realize, especially at a young age. Like, oh, they're just they're just eating. This is what people do. They eat. Noga Schechter 00:10:24 Yeah. Yeah. It's tricky. You know, I think I've done a lot of reading. I mean, I I've read arguably close to four hundred human behavior books. And eating disorders, I think, are one of the most complicated. Monoclonal illnesses out there, and they also have the highest rate of fatality Lorilee Binstock 00:10:49 Yep. Noga Schechter 00:10:50 out of all dental onagers, and there's only a six percent I think it's something between six and eight percent of all people with with this disease heal. Meaning the healing rate of Lorilee Binstock 00:11:09 Yeah. Noga Schechter 00:11:09 of of this is virtually impossible. And and I think the reason that is is because there there's a few things. Right? One is society. Actually, so many people have anything disorders. They just don't even know it. Right? Like, Lorilee Binstock 00:11:28 Yeah. Noga Schechter 00:11:29 the way that we the way that we treat food and the way that we have anxiety any any anxiety over food is essentially part of that disease. Lorilee Binstock 00:11:43 Mhmm. Noga Schechter 00:11:44 So so it's not just the person that overeat, it's the person that's not restrict. It's also the person that is at the gym constantly and is only eating chicken and broccoli Lorilee Binstock 00:11:51 Right. Noga Schechter 00:11:55 saying that this is the healthy way to be because that's the other side of the anxiety. Right? You're still having you're still attaching Lorilee Binstock 00:12:02 Yeah. Noga Schechter 00:12:05 unhealthy anxiety around food. So it's not just over eating, and you're overweight. It's super, super, super skinny or super, super, super muscular. Lorilee Binstock 00:12:17 Right. Noga Schechter 00:12:17 You know, all of that's super, super, super, anything is is related. And so I think I think it's society telling us, you know, how to act with food that makes it difficult. But I think the other piece that makes in any sort of so difficult is it involves self loading, and self loading is probably one of the most complicated scenarios to to to unwind. Because you couldn't be further from the truth. Right? So so so so so I think the the more we gravitate from the truth. Truth of the universe truth of what is Lorilee Binstock 00:12:55 Yeah. Noga Schechter 00:13:03 the sicker we got. Right? So self loathing Lorilee Binstock 00:13:06 Yep. Noga Schechter 00:13:07 takes everything about you and hates it. Right? So when you're eating this order, it's not I oh, I'm eating too much. It's I hate myself twenty four hours a day. And and and that and that's impossible. Right? Because to think about it. You know, it's sunny it's sunny over here in California, and it's raining in New York. Somebody is being born and somebody is dying, and I may be overweight, but I might have nice hair. I might be overweight, but I have a great sister. When you take all of that and just say everything sucks and I sucks. How do you unwind that? It's so so suffered. It's so distant from the truth. Lorilee Binstock 00:13:53 Yeah. That's so interesting. Noga Schechter 00:13:54 And that's, I think, the most I think, that's the most complicated part of the eating disorder because The only way to unwind it is one strand at a time. Yes. Yes. I'm three hundred pounds, but my hair is beautiful and curly. Step one. Step two. Yeah. Yes. I'm three hundred pounds. But, you know, I have great skin. Yes. Yes. I'm three hundred pounds. My grandmother was wonderful. Like, just starting to just pull apart the thought into something more realistic, which is so many different things can can can be true at the same time. But when you're self loading, everything is clumped into one terrible thought, and and it's it takes a very long time, time line. And I think that that's why it's one of the most complicated mental illnesses to carry. Lorilee Binstock 00:14:45 That's so interesting when you say, like, the self loading and the clumping and putting it all together. Because there are times when I am, like, so angry, Noga Schechter 00:14:50 Oh, yeah. Lorilee Binstock 00:14:53 And even though I know that I enjoy multiple things that's happened in the last few days, all of a sudden it's like, god. Noga Schechter 00:14:57 Yeah. Lorilee Binstock 00:15:01 My life sucks. Everything everything's everything's so screwed up. But the truth is, it's like, Noga Schechter 00:15:02 Yeah. Yeah. Yeah. Lorilee Binstock 00:15:07 it feels like that now. Feels like that when things when you feel like you're stuck, but the truth is there were so many wonderful things dispersed in all of the that that emotion And you're right. It's really hard to unravel that. Noga Schechter 00:15:20 Exactly. Exactly. Exactly. I I I you know, some people call it black and white thinking. Lorilee Binstock 00:15:29 Mhmm. Yep. Noga Schechter 00:15:31 It's it couldn't be further from the truth of the universe. It couldn't be further from the truth to to to generalize and to clunk thought. But when you clunks thought to I hate myself all the time, where do you do with that? Where do you go with that? Because she leaves processing that is so can be very difficult. Lorilee Binstock 00:15:53 Yeah. Because I guess you just focus on the one thing that ruins everything. Right? Noga Schechter 00:15:59 Yeah. Yeah. Lorilee Binstock 00:15:59 And so then you go to every extreme. Noga Schechter 00:16:02 Every aspect of you. You're rejecting your entire self in this universe. And the last step to that is eating. Right? Like, the food, the restriction of the food, or they're eating too much, or they're only eating specific food, that's the last piece of this of this disease. It's just, like, the very last outcome. The core of it is rejection of or the core of it is is is the inability to process the way you're processing information from the outside world into the inside is Lorilee Binstock 00:16:44 Yeah. Noga Schechter 00:16:45 yeah. Yeah. Lorilee Binstock 00:16:47 When did you realize that this was the something needed to change? You said you were over three hundred pounds at one point. When when were you like, wow. I really need need to make a change in my life. Noga. Noga, are you there? No. I think I lost you or maybe you are talking, and I'm no. Were you there? Let's hold on just a moment. Let's see if we can get her back. Noca, can you are you still there? Nogue, are you still there? May I get you? Noga Schechter 00:18:31 I happened. What a glitch. Okay. I'm back. I'm back. Lorilee Binstock 00:18:35 Oh, okay. So, yeah, so I was getting I'm sorry for I can hear you perfectly. Noga Schechter 00:18:40 Do you hear me okay? Lorilee Binstock 00:18:45 What my last question before it dropped was What changed? What made you realize that a change needed to be made? Are you there? Something happened? Noga, can you hear me? Think we've run into an issue. Noga Schechter 00:19:31 Lorly, do you hear me? Lorilee Binstock 00:19:33 I can hear you. Can you hear me okay? Hello? Hello? Can you hear me? Noga. Nogie, can you hear me? Hello? Noga, can you hear me okay? Noga Schechter 00:20:18 Hello? Lorilee Binstock 00:20:18 Hello? Can you hear me? Can you hear me? Hello? Noga, can you hear me? Noga, can you hear me okay? Hello, Noga? Nogou, are you there? Can you hear me? No wonder what's happening. Hey, Noga. Noga Schechter 00:22:17 Do you hear me, Lauraly? Lorilee Binstock 00:22:20 I can. Can you hear me? Noga Schechter 00:22:22 Oh my gosh. We're back. Lorilee Binstock 00:22:24 Oh, we're back. You hear me? Can you hear me? Noga Schechter 00:22:26 I can hear you. I'm so excited. Lorilee Binstock 00:22:27 Oh, okay. Noga Schechter 00:22:29 That's so weird. Lorilee Binstock 00:22:30 No. No worries. Noga Schechter 00:22:32 What was that? The universe doesn't make mistakes. Lorilee Binstock 00:22:33 Yes. Well, I want yeah. I I I don't know if you heard my last question, Noga Schechter 00:22:41 Mhmm. Lorilee Binstock 00:22:42 but I did wanna ask when you when did you realize that you needed to make a change. I know you there was a point you said that you got to three hundred over three hundred pounds. Noga Schechter 00:22:48 Yeah. So I had lost Lorilee Binstock 00:22:54 Was it run then? Noga Schechter 00:22:55 well, so I lost a hundred and fifth fifty pounds with a trainer. And eating all the right foods. That took me about thirteen, fourteen months to do naturally. And then shortly after I found myself about seven months later, gained all of it back plus some. And there was this area. There was a point in my life where I was I was Lorilee Binstock 00:23:26 Mhmm. Noga Schechter 00:23:30 I was right back to where I started. I was I was eating just to fall asleep. And I remember waking up in the morning one day in the rented apartment I was living in Los Angeles, and I was, like, choking on last night's food. And I remember I lived by the beach, and I and I went to the beach. It was, like, sunset. I don't know if you've ever seen a California sunset. It's gorgeous. It's, like, blue. It can turn blue and purple and orange, and and I was sitting outside. And I said, I had this I I don't wanna call it an aha moment because I hate when people Lorilee Binstock 00:24:10 Yeah. Noga Schechter 00:24:12 say that. We're such pro we're everything is such progression. You know? But Lorilee Binstock 00:24:17 Right. Noga Schechter 00:24:18 I I did have this moment where I where I said to myself something else is really wrong here. It's not food. It's not what I'm eating. It's not the exercise. Like, something is wrong way past my ability to understand what is wrong. So that was the moment where I first fully understood that I was in a construct. And and so a lot of the spiritual teachers talk about this. I I I I at this point, I was not under any spiritual guidance or I I would I didn't have a spiritual teacher. This is all just very independent. But I I had realized that the entire way I was processing information was off. The entire identity was off. And it's because I was sitting there, and I and I I remember I had this very spiritual awakening. I was looking at the sunset, and I was looking at how beautiful it was. And then I was I was looking at yeah. I was looking at the sunset. I think my dad texted saying it was snowing in New York. Lorilee Binstock 00:25:41 Mhmm. Noga Schechter 00:25:42 And then I was looking at the ocean, and I was feeling my pain. And I there were so many different things going on at one time. That I then asked myself if there's so many different things going on at one time in this very moment, how can it be that I suck all the time. How can that be possible? If if the sunset over there is really, really beautiful, and that ocean is really, really beautiful. And my dad is texting me about snow. And there are there are so many different things going on right now. How is it? That no good sector sucks twenty four seven. And I have this moment where I'm like, that's impossible. That's far that's not the truth. So why do I keep thinking it? And then I realized I was sick. My brain was sick. The way I was thinking about things was sick. I I was sick. I when I say sick, I don't mean I'm disease. I'm the problem. I I don't mean in that way. I mean, the tools that were I was separating and the tools that were giving to me to do this whole adult life thing were not the correct tools. Lorilee Binstock 00:26:52 You are suffering. Noga Schechter 00:27:00 And they were harming me. And and and I think that was the first moment where I realized that my eating disease and my eating order and all the way in on my body and all these things that I hated so much about myself, had nothing to do with who I really was. Lorilee Binstock 00:27:16 Right. Noga Schechter 00:27:21 And so I checked myself into that week, I checked myself into an eating disorder facility. With a white flag up all the way to the moon. And I remember walking into that place saying, please teach me how to live. Because I don't I don't know how I don't know how to live. And I Lorilee Binstock 00:27:42 No. Noga Schechter 00:27:48 I haven't been in a sense. Lorilee Binstock 00:27:50 Wow. So how did you change your relationship with food because we are exposed to food all the time. And Noga Schechter 00:27:52 Yeah. Yeah. I just had this conversation with one of my coaches a few weeks ago. It was the best conversation. I think we've both had in a long time. Lorilee Binstock 00:28:07 I'd love to hear it. Noga Schechter 00:28:08 Yeah. I'd love to share it. I think the way to heal this isn't just for eating disorder. This is for anything in life. I think the way to heal is to just become indifferent. To the outcome. And so what do I mean by that? I eliminated all anxiety around food. There is no anxiety around food in my brain anymore. I eat cookies. I eat adjust ate of agave potato chips like twenty minutes ago. I eat pizza. I eat pasta. Of course, I eat healthy most of the time. Right? But I eat healthy most of the time out of the place of self love, not out of the place of anxiety, self hate. Lorilee Binstock 00:28:54 Mhmm. Noga Schechter 00:29:02 I hate my body. I want my way smaller. I don't do that anymore. So so I I eliminated the entire story around food because the story I had around food was was skewed. It wasn't healthy. So Lorilee Binstock 00:29:17 Mhmm. Noga Schechter 00:29:19 then I realized I was with this trainer who was trying to pack another story about food. A different story. Like, protein and no carbs at night and you know, like, all that story. And then so so so if you have a broken spirit and then you have a broken story about food on that sits on top of the broken spirit. And then you go seek help, and then you get another broken story to put on top of the broken story, on top of the broken spirit, of course, you're gonna wanna gain your way back. Of course, because now your spirit is double broken. Lorilee Binstock 00:29:59 Mhmm. Noga Schechter 00:30:04 Right? Because you just you just pour you just packed another story Lorilee Binstock 00:30:05 Yeah. Noga Schechter 00:30:09 on top of the broken spirit around food. So what I realized is none of the stories are true. The body knows once you quiet down the anxiety. The body knows exactly what it wants. When it when it needs it, what it wants. It knows exactly what to do. And if it doesn't, if it doesn't, that usually means there's a hormonal imbalance, which is great news, great news because if there's a hormonal imbalance, there's ways to treat that. Lorilee Binstock 00:30:41 Mhmm. Noga Schechter 00:30:42 Right? But if there's no hormonal imbalance, Lorilee Binstock 00:30:43 Right. Noga Schechter 00:30:45 then the body if once you quiet down all the anxiety and all the stories around food, it knows intuitively exactly what it needs when it needs it. And that's that's the journey I went on because I realized that my spirit was broken. And and it hadn't and and so it was the stories around food that I just had to completely eliminate. And and I I I've spent a decade doing that. Lorilee Binstock 00:31:00 So And how do you change those stories? And is is is that what eliminated the anxiety? Is that the is is eliminating the story exactly what's going to eliminate the anxiety around the food. Noga Schechter 00:31:24 Yeah. I wish it were that simple. I wish. I wish I were that simple. The the stories go away when the body normalizes. So everyone's body every human body has a natural balance. For instance, I'm never gonna do that skinny. It's not no it's not my the nature of my body to do that skinny. It's never gonna happen. And if I if it does happen, I may be abusing myself somehow. Right? Because so the most so so what you wanna do first is just what I did, for instance, is I I just treated all food that it would break down in a certain way. And I I did retrain myself into feeling full. So the feeling of full is something that I used to ignore. So, you know, you wanna get past the point of self harm. And so that takes therapy, Lorilee Binstock 00:32:21 Mhmm. Noga Schechter 00:32:22 meditation, being present, starting to challenge your thoughts. You know, we talked about the spaghetti, the pulling out, the loathing. Right? So one strands out of time. I was just evaluating things that were great. And then the things that weren't great, instead of hating myself for them, I attached incremental actions on how to essentially fix them, which I'm still doing at thirty nine years old. Lorilee Binstock 00:32:47 Yeah. Noga Schechter 00:32:48 I'm still doing it. And so what happens over time is the body normal lives, and then you realize, wait if I eat a slice of pizza, I'm not gonna gain five pounds. That's that's not what happened. Maybe you do for, like, a day because you're bloated or whatever, but that's not what happens. Pizza actually is part of the universe. So here's the truth about pizza. It's part of the universe, and it breaks down in in your body as nutrients. It that's the only truth about pizza. And and your body does need a balance of nutrients if you eat pizza. The body will know if you listen to it that that was a lot of carbs, and you might need it'll it might start to crave some chicken. Mine does. Right? So if I if I'll have pizza a few hours later, Lorilee Binstock 00:33:33 Mhmm. Noga Schechter 00:33:35 like, clockwork. I'll want some chicken or steak or some kind of protein Lorilee Binstock 00:33:39 Right. Noga Schechter 00:33:40 to balance. But take all of those together, and it breaks down into nutrients in your body. I don't attach the pizza as bad, steak as bad, or only eat potatoes at this hour. I don't do that anywhere. I let my body decide. Lorilee Binstock 00:33:57 So is it So when it came to the trauma, did that is is that part of the strand of Noga Schechter 00:34:02 Yeah. Lorilee Binstock 00:34:06 of working each and every bit of trauma that you've experienced out. Noga Schechter 00:34:14 So with trauma relief and trauma healing, first of all, I'm to go viewing that. So That's like a never ending. Lorilee Binstock 00:34:23 It's a constant right. It's a constant journey. Noga Schechter 00:34:24 It's a constant. And and you and you and I talked about this. Right? Like, it's a constant journey. And and and nobody no. First of all, I do wanna tell if any if anyone is suffering from an eating disorder, I just wanna tell you that's beautiful, great news. Because you're gonna have the best journey of your life or healing, and and and it it's such a guest. It's a different way of living. But when it comes to trauma, you know, sometimes you have it in early life. Sometimes you have it midlife and sometimes you have it later. It's only a matter of when. Right? It's not if. It's what. So Lorilee Binstock 00:35:02 Mhmm. Noga Schechter 00:35:05 the thing about early life trauma like my like, I have what they call complex trauma because it's not necessarily what what I got. It's what I didn't get. Lorilee Binstock 00:35:13 One event. Noga Schechter 00:35:16 Right? Lorilee Binstock 00:35:17 Mhmm. Noga Schechter 00:35:19 And and the thing about that is, you know, you your first three years of life, your first, like, you know, decade of life, you're coming in from the spirit world or the animal world, as a newborn baby, and then your guardians are then helping to shape your egoic construct to make you successful or make you give you the ability to do well in the man world the man made world, which is what we live day today. So I lacked those skills. So it wasn't just about, you know, sitting with the pain, processing, the trauma. I was also re engineering how how I am to behave. Right? Like, Lorilee Binstock 00:36:03 Mhmm. Noga Schechter 00:36:04 my soul knows the truth. How do I take that truth and then integrate it in my day to day? Well, if your parents didn't appreciate you for who you were or didn't let you be who you were, you're gonna be hiding that, and you're gonna be hiding behind these actions that are not true to who you are, and that's when eating starts and the inability to process starts. And so it's also the reverse reengineering of that of going back to almost when I was a child saying, okay. How do I learn now? How to be true to myself? How do I learn if I feel something, if my soul is telling me something, if if I feel spiritually about something, that that's a signal. That that's a signal of who noga is. How do I take that signal and push it out into my day to day? That's the healing of the trauma passed the sit passed the the the healing of the pain. Right? So it kinda comes in two stages. Lorilee Binstock 00:37:05 Mhmm. Noga Schechter 00:37:08 I can't reiterate enough how much I'm still doing that till this day. Lorilee Binstock 00:37:12 Yeah. Yeah. It is an ongoing journey. It's one of those things that it's, like, you know, three steps forward, two steps back, four steps for. It it Noga Schechter 00:37:16 Yes. Lorilee Binstock 00:37:22 it's constantly changing. I think that's that was a big thing for me to understand. Noga Schechter 00:37:26 Yeah. Lorilee Binstock 00:37:27 Was that oh, I three steps forward, I failed because that's not how it works. And and I feel like I I feel like people told me that it just never clicked, and then one moment it did click, and it was like, okay. I you know, I'm gonna have setbacks. How am I going to pick myself up? And Noga Schechter 00:37:36 Yeah. Lorilee Binstock 00:37:49 learn from whatever setbacks. So, you know, the next time, I'm at least four steps forward before I go a couple steps back. Noga Schechter 00:37:57 Yeah. I I I struggle with it too even till this day, but I think the biggest part is I no longer use food to help process those days. Lorilee Binstock 00:38:08 Mhmm. Yes. Noga Schechter 00:38:09 Now I now I sit with the actual feelings, and then I try to integrate into my day, that's that's the the healing of the eating disorder. By the way, on the flip side of the coin, that's the gift. That's the gift because in this life, very few people get an opportunity to live that authentically to learn how to align themselves with the true essence of who they are into their day to day. It's like we we have no choice but to live with intention. Lorilee Binstock 00:38:48 Mhmm. Noga Schechter 00:38:50 And so I think, you know, I remember being in treatment, and they were like, they gave me this book. I forget the name of it because I just wanted to throw it across the room. Lorilee Binstock 00:38:58 Yeah. Noga Schechter 00:38:59 And it was it was, like, something about having an eating disorder as a gift. And I was, like, Lorilee Binstock 00:39:05 Oh, I could see where you'd be like, oh my god. You're not there yet. Right? You're not there yet. Noga Schechter 00:39:06 Like, I'm like, how does it get worse than myth? You know? Wow. It's so true. It's so true because you have, you know, to heal. There's no choice but authenticity. Like, I can't even I can't even work Lorilee Binstock 00:39:22 Right. Noga Schechter 00:39:25 on things I don't believe in. Lorilee Binstock 00:39:28 That's a good thing. Noga Schechter 00:39:28 I can't I can't even have a job or, like, I don't wing So everything has to be true because the the thing about overeating or restricting or anything along those lines is that is the last piece, as I mentioned before, it's the last piece of the problem. Right? Lorilee Binstock 00:39:45 Mhmm. Noga Schechter 00:39:46 So So it's a it's been a gift. You know? But the the weight came off a second time through this the the spiritual healing. Lorilee Binstock 00:39:58 And it stayed off. Noga Schechter 00:39:58 And oh, yeah. Oh, yeah. Oh, yeah. Now I exercise every day. I exercise Lorilee Binstock 00:40:02 That's the thing. Noga Schechter 00:40:05 every day. That's it. That's crazy. If you were to tell me ten years ago that I would be waking up every morning at four thirty to make a five AM hit class, I would I would have called you the biggest lawyer in the world, and it's it's interesting. All the anxiety around exercise has gone too. Like, I don't I don't wake up saying, oh, I don't feel like going to the gym. I don't wake up saying, oh, I have to go work out. I don't do any of that. I I wake up and I go, okay. It's time to get up. My body needs to needs some energy. Let's go give it some energy. Lorilee Binstock 00:40:43 Mhmm. Yeah. Noga Schechter 00:40:46 You know? It's Lorilee Binstock 00:40:48 It's it's it's it's interesting how things change when you start to heal, and I think it's it's hilarious what you said about the book when you first got it because you're still in the beginning of the journey. It's like when I was driving in through the gate, at my residential treatment center for trauma. Noga Schechter 00:41:03 Yeah. Lorilee Binstock 00:41:05 It says, expect a miracle to the front, and it was it's this big sign. Noga Schechter 00:41:09 Oh, oh, that's the you're like, are you crazy? Lorilee Binstock 00:41:10 And I was just like, oh, exactly. Noga Schechter 00:41:13 Like, miracle your way over to the Atlantic Ocean. Okay. Like, Lorilee Binstock 00:41:19 Yep. It was it I I read I will never forget thinking what is whatever. And then leaving when I left was when I was, like, I get it now. I get it now. This is what it's like to start healing. I was there for thirty one days, Noga Schechter 00:41:31 Yeah. Lorilee Binstock 00:41:35 and Noga Schechter 00:41:35 Oh, you were. Okay. Can I okay? Let me ask you a question. Lorilee Binstock 00:41:36 I was there for Noga Schechter 00:41:39 I wonder if you relate to this, but Lorilee Binstock 00:41:41 Yes. Noga Schechter 00:41:43 Do you look back do you look back at treatment and and tell yourself everyone should do this? Lorilee Binstock 00:41:51 I do. I do. I do. I I feel very fortunate that I was able to, and, you know, I'm careful because Noga Schechter 00:41:55 Right. Lorilee Binstock 00:41:58 I, you know, I wish I could tell everybody, and and insurance does cover it for the most part, but there are a lot of people who can't afford it. Right? So, you know, no. When I got out, I was like, oh my gosh. Whenever I knew someone whenever I talked to someone who is struggling, like, you need to check this place out. Noga Schechter 00:42:05 Right. Right. Totally. Totally. Lorilee Binstock 00:42:15 It's it's it's not cheap. If if insurance won't cover it, it is it's real it Noga Schechter 00:42:16 Right. Right. Right. It's it's astronomical. It kinda makes you wonder Lorilee Binstock 00:42:21 but everyone needs it. Noga Schechter 00:42:23 it yeah. And it just makes you wonder how lacking that education and that's you know, Lorilee Binstock 00:42:28 Exactly. Noga Schechter 00:42:29 it's just so lacking. You know, even till this day, I just found a coach who's probably the best coach I've ever had in my life. Okay? It's taking me thirty nine years to find them in, like, thirteen cities. Right? Like, so so we have to search through the crevices to to get to sometimes get the treatment that we need. And that that makes me sad. Lorilee Binstock 00:42:54 And it does. It's very sad. I went to I went to a step down program Noga Schechter 00:42:55 Yeah. Lorilee Binstock 00:42:59 right after. Right? I went to full residential treatment, and then I had to go somewhere else for a partial hospitalization to kind of just wean my way out of it. Noga Schechter 00:43:07 Yeah. Yeah. Yeah. Yeah. Lorilee Binstock 00:43:09 And it wasn't the same. I I I was like, you know, no. I went to this place, and I was like, Noga Schechter 00:43:11 No. No. It's not. Lorilee Binstock 00:43:16 if I went here first, I would not be where I am now. So that's another thing. You have to weave through the hundreds and thousands of treatment centers out there, and I think that's also the hard part because then you spend your money on a place, Noga Schechter 00:43:25 Yeah. Lorilee Binstock 00:43:33 that is that you it gets decent reviews and good reviews even, but your it doesn't really fully teach you what some others do. Noga Schechter 00:43:44 Okay. Yeah. I think you know the the other tricky part about all this is that it's so individualized, and everybody has different needs. You know? And and so, like, I can generalize Lorilee Binstock 00:43:52 Right. Noga Schechter 00:43:55 a hundred times over and over, but everybody gets different things from different places. And I think we just I, for some reason, you know, I'm a very, very spiritual person. I mean, to the tenth power. This whole process has made me believe in the universe. You know, I believe if you were to see my before picture and you were to see me now, it's not a typical before and after. I look absolutely nothing like I did. Lorilee Binstock 00:44:25 What what happens? Noga Schechter 00:44:26 That's, like, Lorilee Binstock 00:44:27 I'm just curious. What happens when you look back at those the old your old photos of you? Because they're they are drastic, and I am going I I'll try to put it up. I'm gonna try to put it up on the thing. But Noga Schechter 00:44:28 Yeah. I don't eat. It is plastic. Yeah. Yeah. Lorilee Binstock 00:44:37 how do you feel when you look at those older pictures? Noga Schechter 00:44:40 Interesting question. I just I don't even remember those times. Because I was in so much pain all the time. It it just it scared my ability to even, like, have that much of a memory. Lorilee Binstock 00:45:05 Mhmm. Noga Schechter 00:45:05 I just know that the biggest changes that were made the the one thing I would do think about is that the biggest changes that were made from them to now were not physical. They were not concentrated on food. Or exercise. They were concentrated on finding my truth, connecting with my soul, working on building better friendships, working on on on a construct, like, when we say, you know, the some of the tech geeks out there or people have to say sometimes we're it could be we're in a simulation. We are in a simulation. You're in the simulation of your ego. So so so when I look back when I look back at those photos, Lorilee Binstock 00:45:49 I'm just saying, yeah. Noga Schechter 00:45:53 I just think of all the work I've done reconstructing every aspect of my life, one at a time, and down to I mean, how I how I think about movies and what TV shows I watch, and there's specific music I stopped listening to. Like, certain clothes I won't buy. Like, there's just things that like, I just say, what supports my best self? And and though when I look back at that picture, I think about how different that journey was in comparison to eat this, eat that here at your plan, go to the gym twice a day, see the trainer four times a week, spend all your money on. You know? It's so different. Lorilee Binstock 00:46:40 Well, Noga Schechter 00:46:41 Yeah. Yeah. Lorilee Binstock 00:46:42 what a transformation? I think it's It's amazing. Noga Schechter 00:46:44 Uh-huh. Thank you. Lorilee Binstock 00:46:46 More so emotionally and mentally, which is so impressive, Noga Schechter 00:46:49 Yeah. Thank you. I'm impressed with you. Lorilee Binstock 00:46:51 and so so much to be proud of. Noga Schechter 00:46:54 I'm impressed with you and your podcast and your and your insider magazine and the fact that you let people speak about these things Lorilee Binstock 00:46:54 Oh, you're so sweet. Noga Schechter 00:47:02 I wish we had more outlets. I wish people knew that it's totally okay to be going through this stuff so many people do. And I think the more we speak about it, the better it is for others. Lorilee Binstock 00:47:12 Yeah. Yeah. Yeah. There's a in my upcoming magazine, there was a contributor, Rachel Lemmon, who writes about vicarious resilience. The more you listen to other people or see other people's resilience, it builds a little bit of resilience in yourself to help you get to that point. So, yes, we need to keep talking. We need to keep sharing these stories. I think it's extremely important to help so many other people. So thank you. Nope. Noga Schechter 00:47:45 I agree. Oh, with pleasure. With pleasure. I just wish anybody that's going through this knows that It's an absolute gift, and only the the only only the best is yet to come. Lorilee Binstock 00:48:00 Amazing. Well, thank you again for joining me today. I really appreciate it. Noga Schechter 00:48:05 Thanks for having me. Thanks for having me. Have a great rest of day. Lorilee Binstock 00:48:08 Absolutely. You too. Noga Schechter 00:48:11 Okay. Lorilee Binstock 00:48:11 That was Noga Shector, mental health and disordered eating advocate. For more information on Noga, you can click there on the scrolling fortune cookie on your screen. Also, Mace issue of Authentic Insiders is out. Check out authentic Insiders at trauma survivor thriver dot com. That's trauma survivor, thriver dot com. If you haven't already, please subscribe to my email list to get authentic insider in magazine in your inbox monthly. Thank you for joining me today. Join me live next week when I speak with Kenneth Nixon Jr. Author of Born into Chaos as he shares his experience with a mother who was mentally ill and how he thinks the mental health care system can be fixed. You've been listening to a trauma survivor Thrivers podcast on Fireside. I'm Laura Lee, Ben Stock. Thank you for being a part of the conversation. Take care.
Sorry for my absence, my last video on YouTube was taken down. I received monoclonal antibodies. These are not the same as the antibodies given to people to treat COVID, but for COVID prevention. Monoclonal antibodies are given to folks for whom standard vaccines won't work or who are severely immune compromised. You may remember that on my last trip to Seattle I learned that while I have had 4 COVID vaccines/boosters -- I had almost no protection. My chemotherapy agent, Rituxan, keeps B cells from replicating/maturing. My community, Eugene/Springfield is about 235,000 people. We have one place administering these treatments and my wait was about a month to receive the treatment. Ours is being offered at a Hospital Infusion Center. I was given 4, 1.5ml vials of the Evusheld treatment in two injections, given in the rump. While it was quick to administer, I was kept for more than an hour to make sure that I didn't have any injection reaction, anaphylaxis, rash, etc. Not only did I not, in the coming days, I didn't even have the difficulties I've had with the vaccine -- like tenderness at the injection site, fever, flu-like symptoms, etc. The protection is similar to the vaccines in that it prevents the worst of disease and death but not great protection against the newest variants. Also, similarly, it needs to be readministered after 6 months. Are you eligible for monoclonal antibodies? Have you had them? What is your experience? I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you.
Monoclonal antibodies were a key tool in the early pandemic response, but are now ineffective against new variants — putting immunocompromised patients at risk. Thanks for listening to WIRED. Check back in tomorrow to hear more stories from WIRED.com.
Monoclonal antibodies were a key tool in the early pandemic response, but are now ineffective against new variants — putting immunocompromised patients at risk. Thanks for listening to WIRED. Check back in tomorrow to hear more stories from WIRED.com.
As we start the new year with a “tripledemic” from the combined threat of RSV, flu, and COVID-19, there's both a sense of hope and concern. There's hope that flu and RSV surges are now declining after a peak earlier in the season and there's concern among the immunocompromised community that the general public has moved on and are no longer taking COVID-19 safety precautions. "It's January. January is a time when viruses tend to promulgate. We're certainly in the midst of another wave when it comes to COVID, and if you want to stay safe, you're going to have to keep a mask on. A nice, good, tight-fitting mask, whenever you're in public,” says Steven Newmark, Director of Policy at GHLF. “And, unfortunately, there aren't too many other ways to mitigate [risk] in our society." Among the highlights in this episode: 2:33: As society moves on and fewer precautions are being taken to fight the COVID-19 pandemic, flu season started early in the U.S. this year 3:28: Cases of respiratory syncytial virus, or RSV, have been declining 3:56: At its peak, in mid-November of 2022, new RSV hospitalizations reached an all-time high of 70 children hospitalized per 100,000 infections. Historically, peaks have been anywhere between 26 and 52 children per 100,000 infections 5:02: “Another thing that's somewhat positive, the severity of the flu this year is not particularly high. They are on track for a mediocre season when it comes to hospitalizations. So that's a good thing as well, of course, and not to minimize what is happening out there. We've already lost 13,000 Americans to the flu this season. 61 of those were children,” says Steven Newmark 5:58: There is a high possibility that a second flu strain could be coming our way 7:37: Omicron subvariants continue to spread, especially the subvariant XBB.1.5 which seems to be circumventing immunity from vaccination and infection 9:38: “I know our chronic disease community really is there for each other, and it's amazing to have that support, but it's not as strong with the general public. So as we're in this new year, and people continue to get over COVID, I just want to say that… we're here for you and we understand you and we're going to keep talking about and providing tips and health advocacy for… fighting this virus together!” says Zoe Rothblatt, Associate Director of Community Outreach at GHLF 10:32: A recent study shows those who were vaccinated and received a bivalent booster have an 18.6 times lower risk of dying from COVID-19 compared to those who were unvaccinated. The risk of infection is also three times lower when people are vaccinated. 11:05: Monoclonal antibodies, including Evusheld, have lost potency against new omicron subvariants 12:18: “There are a lot of people out there getting sick, and there is still plenty of winter season left. As a listener of this podcast, you know what to do: make a plan with your doctor, make a plan with your family, make a plan for yourself and be ready,” says Steven 12:46: The impact of the new congress on legislation work 13:12: The Safe Step Act remains one of the legislative priorities for GHLF in 2023 15:15: Could the results of the mid-term elections have an impact on COVID funding? 16:37: To get involved with our advocacy work, visit 50statenetwork.org or send an email to advocacy@ghlf.org 17:49: More on GHLF's advocacy work at the state level 18:46: What our hosts learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco, the drug's overall efficacy profile, as well safety information and the rates of ARIA, and more. Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023. In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group. Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia/Alzheimer clinical focus page: neurologylive.com/clinical/dementia-alzheimer Episode Breakdown: 1:20 – Lecanemab's safety profile from Clarity AD 4:15 – Amyloid-related imaging abnormalities and lecanemab use 6:40 – The landscape of Alzheimer disease therapeutics 8:10 – Neurology News Minute 10:15 – What research has revealed about treatment approaches 13:00 – How clinical trials have evolved in dementia research 14:40 – The possibility of induction therapy in Alzheimer disease 16:30 – Looking ahead to the next steps in treatment development 18:00 – Progress toward treating Alzheimer disease earlier This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment Seizure-Free Days and Duration Intervals Increased with Fenfluramine in Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE 1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.
TWiP solves the case of the Man from Hong Kong with Multiple Comorbidities, and discuss safety and efficacy of a monoclonal antibody against malaria in Mali. Hosts: Vincent Racaniello, Dickson Despommier, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Monoclonal antibody against malaria trial (NEJM) Hero: Stephen Hoffman Letters read on TWiP 211 Become a patron of TWiP Case Study for TWiP 211 Man in his 20s originally from Mali who comes in with a dermatological complaint about 1 mo after he returned from spending time in Bamako, Mali with friends and family. Reports this has been going on for months and he is getting very frustrated as he is not getting any answers. He relates that this started with itching over a “blackhead” resembling a pimple that was itchy and very small. Over the subsequent months it started to get larger with ongoing itchiness but no pain. No erythema or warmth in the area. Other lesions developed in addition to the first one. There was no drainage from the skin lesions. He started putting triple antibiotic ointment on his lesions that he bought from a pharmacy. He then went to his primary doctor who prescribed a topical medication and PO antibiotics but this did not help. He reports that when in Mali he stayed in his house with his parents, siblings, grandmother and other extended relatives – more than 40-50 people under one roof. food made by his family, reports consumption of only cooked meat, no uncooked meat. Ate salads and uncooked vegetables. No contact with any animals, no pets in the home. Denies any contact with any pets or farm animals such as pigs, cows, horses, cattle. Denies swimming in any lakes or ponds. No hiking or outdoor activities. No riding horses. Was sexually active in Mali with women and is HIV negative. On examination he has a 10 cm lesion over anterior L thigh, with verrucous and vegetative appearance with yellow crusting over central area and heaped up lesion, not undermined. No erythema, warmth or drainage. Has a similar smaller lesion measuring about 3 cm on R flank. Has a 3rd smaller lesion with some mild crusting and about 2cm over R posterior thigh. He ends up getting a biopsy that reveals: HISTOLOGIC FEATURES That ARE NOT DIAGNOSTIC. THERE IS NO EVIDENCE OF any specific organisms. THE EXOGENOUS MATERIAL WHICH COULD REPRESENT SOME TYPE OF FOREIGN BODY IS NOT IDENTIFIABLE AS PART OF A FLY OR ARTHROPOD, NOR IS IT TYPICAL OF A SPLINTER AND ITS PRESENCE IN THE SPECIMEN MAKES IT PROBLEMATIC AS TO ITS SIGNIFICANCE. MICROSCOPIC DESCRIPTION: WITHIN THE DERMIS THERE IS A DENSE DIFFUSE MIXED CELL INFLAMMATORY INFILTRATE INCLUDING MANY PLASMA CELLS AND NEUTROPHILS. THERE IS EXOGENOUS MATERIAL. PAS, GMS, FITE AND GRAM STAINS ARE NEGATIVE FOR INFECTIOUS ORGANISMS. Additional testing is ordered that leads to the diagnosis. He is planning on returning to Mali and perhaps sooner than originally planned if he does not get a diagnosis since he thinks the doctors in Mali would know what he has. Send your case diagnosis, questions and comments to twip@microbe.tv Music by Ronald Jenkees
Featuring an interview with Dr Jeffrey Zonder, including the following topics: Biology and symptomology of primary amyloidosis (0:00) Staging and prognosis for patients with amyloid light chain (AL) amyloidosis (10:21) Supportive care for patients with advanced disease (16:25) Current amyloidosis treatment paradigm (21:49) Monoclonal antibody therapy for patients with AL amyloidosis (31:38) CME information and select publications
This week, please join author Sean Pokorney and Associate Editor Shinya Goto as they discuss the article "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial." Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and Backstage Pass of the journal and its editors. We're your cohost. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Carolyn, this week's feature, very interesting topic. In patients that have end stage renal disease that require dialysis, questions emerged should we anticoagulate them to prevent stroke, but of course, there's a risk of excess bleeding. Well, this feature discussion today is a study comparing apixaban and warfarin for anticoagulation in exactly this patient population. But before we get to those results, how about we grab a cup of coffee and go through some of the other articles in the issue? Would you like to go first? Dr Carolyn Lam: Absolutely, Greg. So my first paper is a pre-specified analysis of the Paradise MI trial and knowing you'll likely ask me what that was about, Greg, at least to summarize for everyone, the Paradise MI trial compared sacubitril/valsartan with ramipril and its effect on reducing heart failure events after an MI in more than 5,600 patients with an acute myocardial infarction complicated by LV systolic dysfunction, pulmonary congestion, or both. Now in today's paper, what Dr. Mehran and colleagues found was that among patients with a recent AMI and LV systolic dysfunction, heart failure are both, sacubitril/valsartan decreased the risk of coronary related events by 14% as compared with ramipril over a median follow-up of 22 months. The reduction in coronary events occurred with a favorable safety profile. Dr Greg Hundley: Wow, Carolyn, very interesting. Another indication perhaps for sacubitril/valsartan, especially relative to ACE inhibitors. So what does this mean for us clinically? Dr Carolyn Lam: Well, the results really cause us to consider if in addition to antiplatelets and lipid lowering therapies, sacubitril/valsartan may be explored as a potential agent to mitigate the residual risk in survivors of AMI. Of course, dedicated studies are necessary to confirm this finding and elucidate its mechanism. Dr Greg Hundley: Oh, very nice, Carolyn. Well, my first paper comes to us from the World of Preclinical Science and Carolyn, this study evaluated the scavenger receptors stabilin-1 and stabilin-2, proteins that are preferentially expressed by liver sinusoidal endothelial cells. Now, they mediate the clearance of circulating plasma molecules controlling distant organ homeostasis. And studies suggest that stabilin-1 and stabilin-2 may impact atherosclerosis. So in this study, the investigative team led by Professor Cyrill Géraud from the University Medical Center and Medical Faculty in Mannheim, Heidelberg comprehensively studied how targeting stabilin-1 and stabilin-2 affects atherosclerosis. Dr Carolyn Lam: Huh. All right, nicely explained. And so what did they find, Greg? Dr Greg Hundley: Right, Carolyn. So inhibition of evolutionary conserved class H scavenger receptors, stabilin-1 and stabilin-2, reduced aortic plaque burden in preclinical models and athero protection was mediated likely through down regulation on transcriptional factor ERG1 in monocytes by multifaceted plasma protein changes. And then finally, Carolyn transforming growth factor beta induced periostin, reelin, and they are novel ligands of stabilin-1 and stabilin-2 and are implicated in the development of atherosclerosis. Dr Carolyn Lam: Okay. Wow. Could you give us a take home message, please Greg? Dr Greg Hundley: Right. Carolyn, I knew you had asked me this. So here we go. Monoclonal, anti-stabilin-1 and anti-stabilin-2 antibodies provide a novel approach for the future treatment of atherosclerosis. And in the future, perhaps the plasma proteome composition may serve as a predictive factor, biomarker or surrogate parameter for cardiovascular disease in patients. Dr Carolyn Lam: Wow. Thanks Greg. My next paper is a true story of discovery. Now I could ask you what you know about the condition hypertension with brachydactyly type E... Greg, I love that expression. I wouldn't be able to answer that too. So let me tell you the story. So hypertension with brachydactyly type E is an autosomal dominant Mendelian disease resembling essential hypertension. Untreated patients die of stroke by the age of 50 years. Now, these authors had previously demonstrated a gain of function phosphodiesterase 3A gene mutations that caused the condition by increasing peripheral vascular resistance. They studied a large family with the condition earlier and were puzzled that cardiac hypertrophy and heart failure did not occur despite the decades of hypertension. And so they hypothesized that in the heart, this phosphodiesterase 3A or PDE3A mutations could be protective. Isn't that neat? And so corresponding authors, Doctors Bader, Klussmann, Bähring and Hübner, all from the Max Delbruck Center for Molecular Medicine in Berlin, Germany. So they studied new patients as well as CRISPR-Cas9 engineered rat models of this condition of hypertension with brachydactyly type E. And they comprehensively phenotyped all of them with the human induced pluripotent stem cells carrying these PDE3A mutations as well. So analyzing all of this from cells to new patients to CRISPR-Cas9 models. Dr Greg Hundley: Wow, Carolyn, what an interesting story. So what did they find? Dr Carolyn Lam: So while in vascular smooth muscle, the PDE3A mutations caused hypertension, in the hearts, they conferred protection against hypertension-induced cardiac damage, hypertrophy and heart failure. The mechanism involved long-term adaptations of mRNA and protein expression as well as calcium cycling. Non-selective PDE3A inhibition was a final short term option in heart failure treatment to increase cardiac cyclic AMP and improve contractility. So the data argued that mimicking the effect of PDE3A mutations in the heart rather than non-selective PDE3 inhibition was cardioprotective in the long term. And these findings could indeed facilitate the search for new treatments to prevent hypertension-induced cardiac damage. This is discussed in a really lovely editorial by Dr. Chiong, Houslay, and Lavandero. Dr Greg Hundley: Very nice, Carolyn. Wow. What another... we have such great articles from the World of Preclinical Science. Beautiful description as well. Well, we have some other articles in the issue, particularly from the Mailbag. And we have a Research Letter from Professor Thiagarajan entitled “Yield of Cardiac MRI in a pre-participation cohort of Young Asian males with T-Wave inversion.” Dr Carolyn Lam: Interesting. There's an exchange of letters between Dr. Xu and Huang regarding the article associations of dietary cholesterol, serum cholesterol and egg consumption with overall and cause-specific mortality with a systematic review and updated meta-analysis. There is a Perspective piece by Dr. Marcus on Smart watch detected atrial fibrillation, the value in positive predictive value. Isn't that interesting? And now onto that very, very important question of anticoagulation in patients with kidney disease. Can't wait. Let's go, shall we? Dr Greg Hundley: You bet. Carolyn. Welcome listeners to our December 6th feature discussion. And we have with us today Dr. Sean Pokorney from Duke University in Durham, North Carolina, and our associate editor, Dr. Shinya Goto from Tokai University in Isehara, Japan. Welcome gentlemen. Well, Sean, we're going to start with you. Can you describe for us some of the background information that went into the preparation of your study and what was the hypothesis that you wanted to address? Dr. Sean Pokorney: Yeah, absolutely. Thanks for having me to discuss the renal AF trial. And so I would say that the background information to the study was that we know that atrial fibrillation is an incredibly common condition in patients with chronic kidney disease. And the decision of anticoagulation in patients with end-stage kidney disease, on hemodialysis is really quite complex because these patients are at high risk for stroke and they're at high risk for bleeding. There are concerns with warfarin around calcific uremic arteriolopathy or calciphylaxis and there have been some data including from the original Aristotle trial that apixaban was even more favorable in terms of bleeding reduction relative to warfarin in patients with more advanced chronic kidney disease. Although patients with creatinine clearance less than 25 were excluded from Aristotle and really all patients with endstage kidney disease on hemodialysis have been excluded from all trials of atrial fibrillation in the past. And so we really wanted to evaluate the safety of apixaban versus warfarin in patients with end-stage kidney disease, on hemodialysis. And the hypothesis was that apixaban was going to be non-inferior to warfarin with respect to safety in terms of major or clinically relevant, non-major bleeding in these patients with atrial fibrillation and end stage kidney disease on hemodialysis. Dr Greg Hundley: Thanks so much, Sean. And you've mentioned the renal AF trial. So could you describe for us, for your, I guess, substudy, what was the study population? Who did you include and describe for us also your study design? Dr. Sean Pokorney: Yeah, absolutely. So the trial included patients who had end-stage kidney disease, and/or on hemodialysis, as well as having concomitant atrial fibrillation. And the patients had to have a CHA-VASc score greater than equal to two. All of the patients had to be on hemodialysis for at least three months. So these were chronic hemodialysis patients. And the study design was an open label randomized trial that was 1:1 randomization between apixaban and warfarin with blinded outcome evaluation. And again, the primary endpoint of the study was major or clinically relevant non-major bleeding based on ISTH definitions. And there were secondary endpoints looking at stroke, systemic embolism, death, medication adherence, and I think a really important sub-study looking at PK data. And the goal was to have 50 patients where we included PK data that was going to more represent what chronic apixaban dosing data would look like in these patients with end-stage kidney disease on hemodialysis. And originally the goal of the trial was to include over 700 patients. Originally we were trying to include 762 patients based on our initial power calculations to achieve true non-inferiority. Unfortunately, the trial enrollment was low and so the trial was ultimately stopped prematurely at 154 patients, although we were able to include the original targeted 50 patients in the PK substudy. The dosing that we used in the renal AF trial was 5 mg of apixaban twice daily unless patients had a second dose-reduction criteria in addition to chronic kidney disease. So the fact that they had end-stage kidney disease and were on hemodialysis counted as one dose reduction criteria and patients that were under 60 kilograms or less were 80 years of age or older, who had then a second dose-reduction criteria were treated with the 2.5 mg twice daily dosage. And this was important to note because this is different than the dosage that was used in the AXADIA-AFNET trial. Dr Greg Hundley: Very nice. And so Sean, what did you find? Dr. Sean Pokorney: Yeah. So again, a lot of this data is really exploratory because of the limited sample size, we weren't really able to definitively conclude anything about the major or clinically relevant non-major bleeding rates. I would say that some of the key findings that we saw was that there were high rates of major or clinically relevant non-major bleeding in both arms of the trial and one year bleeding event rates were 25% in the warfarin arm and 31% in the apixaban arm. And again, there was no statistically significant difference, although again, this is really exploratory. I would say that some of the other interesting findings that we saw was that there were very low rates of ischemic and hemorrhagic stroke in this patient population. Again, there were 82 patients randomized to apixaban, 72 patients randomized to warfarin. And there was a difference in the randomization because of the stratification by site that was performed with the randomization. And so within the 82 patients that were randomized to apixaban, the patients, there was one ischemic stroke and one hemorrhagic stroke. There were no hemorrhagic strokes in the warfarin population and two ischemic strokes. Another key finding was the high rates of mortality in this patient population. So 26% of the apixaban patients experienced a mortality event, 18% in the warfarin arm. So again, the mortality rates in these patient populations were extremely high. I would also emphasize some of the data from the PK analysis. So we looked at the PK analysis in two different ways. For the patients that were treated with the 5 mg dose of apixaban, the PK data showed that there was consistent overlap in the steady state concentration at one month compared to patients in the Aristotle trial that had really mild to moderate, moderate to severe and severe chronic kidney disease. And so there was a consistent overlap in those steady state concentrations between the end-stage kidney disease population on hemodialysis and the chronic kidney disease population who benefited from a apixaban in the Aristotle trial. Similarly, in the 2.5 mg apixaban dose, the patient who had a second dose reduction criteria in addition to chronic kidney disease, those patients had consistent steady state concentrations of apixaban relative to patients with mild to severe chronic kidney disease. Dr Greg Hundley: Very nice. Well thank you so much, Sean. And listeners, now we're going to turn to our associate editor, Dr. Shinya Goto. Shinya, can you, sort of, highlight for us some of the interesting findings that you see from these study results that Sean just presented? Dr. Shinya Goto: Thank you, Greg. Thank you, Sean for your wonderful summary of your study. We had a great discussion with an editor for this paper. As Sean pointed out, this is a kind of underpowered trial or just terminated early, hypothesis was not tested in the trial. But this population of patient clearly needs a real-world clinical trial, patient with atrial fibrillation, end-stage kidney disease, on hemodialysis; things a clinician could do. In some country, nephology society defined warfarin contraindicated in this population. As Sean pointed out, whether the development of this trial include this high-risk population patient. So we had a discussion whether the underpowered trial provided something or nothing may be better than something just provided here. Our consensus finally reached was, this limited trial still provide something like, you have to make a decision to use the anticoagulation. I mean, that the apixaban might be still used due to the PK data. That is the kind of interesting point of this trial. Dr Greg Hundley: Very nice Shinya. Well, Sean, turning back to you and Shinya with that nice lead in really, Sean, what do you think is the next study that needs to be performed in this sphere of research? Dr. Sean Pokorney: Yeah, absolutely. I think this is a challenging patient population to study. And again, our trial, the renal AF trial stopped early. Unfortunately, the AXADIA-AFNET 8 study also stopped early, which was also looking at apixaban versus warfarin outside the US and Europe. And so again, it is a challenging patient population to study. But again, I also think it's a really important population to study because one of the main unanswered questions in this population is whether or not they should receive anticoagulation. And so I think that ultimately more work and additional studies trying to determine whether or not these patients truly benefit from anticoagulation or stroke prevention, I think is really one of the critical directions that we need to take the field in. Dr Greg Hundley: And Shinya, do you have anything to add? Dr. Shinya Goto: Well, I fully agree with Sean. I mean, this is a very challenging area and still raising the question whether anticoagulation is necessary or not by your study. Maybe next generation oral anticoagulant such as Factor XI inhibitor that is more elevated to contact pathway may be beneficial. So we really need a good clinical study in this very important and known answered area. Dr Greg Hundley: Very nice. Well listeners, we want to thank Dr. Dr. Sean Pokorney from Duke University in Durham, North Carolina and our own associate editor, Dr. Shinya Goto from Tokai University in Japan for bringing us the results of this randomized open-label trial of apixaban versus warfarin in patients with chronic kidney disease on hemodialysis, revealing high rates of bleeding in both groups, but due to low enrollment, was unable to identify its non-inferiority endpoint. It's important to note, however, as both our author and editorialists have identified further research is really needed in this area to really examine the efficacy of anticoagulation for stroke prevention in this high-risk patient population. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week On The Run. Dr. Greg Hundley: This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Rapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Monoclonal antibody treatment (bebtelovimab)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides:https://bit.ly/3TkT7sJTo view the full online program:https://bit.ly/3TqnNIX
Host: Darryl S. Chutka, M.D. (@ChutkaMD) Guest: Wilson I. Gonsalves, M.D. Monoclonal gammopathies represent abnormal proteins produced by plasma cells. The most common monoclonal gammopathy is monoclonal gammopathy of undetermined significance or MGUS. While MGUS itself is not a malignancy and doesn't require treatment, patients with MGUS have an increased risk of developing a variety of hematologic malignancies and therefore do require surveillance. The topic for today's podcast is monoclonal gammopathy of undetermined significance and our guest is Wilson I. Gonsalves, M.D., a hematologist and oncologist from the Division of Hematology at the Mayo Clinic. We'll discuss how to diagnose MGUS, who is more likely to develop this condition and how patients with it should be followed. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
The Cancer Pod: A Resource for Cancer Patients, Survivors, Caregivers & Everyone In Between.
Curcumin is what makes turmeric orange. It is also a very popular supplement. What does it do exactly? How should it be taken? How is it used in integrative oncology? Can you take it with chemo? Tina & Leah answer these questions and much more in this episode of The Cancer Pod.Want to support the show? Just buy us a coffee!Buymeacoffee and THANK YOU!Links we mentioned on this episode and other cool stuff:A review of the health benefits of Curcumin FoodsTurmeric in cancer care Memorial-Sloan Kettering Cancer CenterA list of Dr. Aggarwal articles that have been retracted PubMedScientific papers peer reviewed, open access onlind PubPeerCurcumin- summary by the National Cancer Institute NCIWhat's the difference between a root & a rhizome? Herb PharmTopical henna and turmeric study Daru J of Pharm Sciences Topical turmeric for mouth sores from cancer treatment Phytother ReviewCURCUMIN- A Chemical and Technical Assessment (CTA) Lead found in Curcumin supplements Public Health Reports Potential of Curcumin in CLL Hematology & OncologyHigh dose Curcumin for Monoclonal gammopathy (myeloma) Support the show
Researchers just published a new study that, for the first time, found a treatment that completely removed rectal cancer in every patient that participated—meaning that every single patient in the study is in remission, with no chemo, no radiation, and no surgery. And even though the study was small, the results are not only heartening, but also, according to the lead researcher, they open up a potential new corridor for fighting cancer—which they will be expanding quickly to treat stomach, pancreatic, as well as bladder cancer. Furthermore, the therapy they're testing (monoclonal antibodies) has none of the toxic side effects of the other treatments currently being used. ⭕️ Sign up for our NEWSLETTER and stay in touch
The Patriotically Correct Radio Show with Stew Peters | #PCRadio
Thursday on the Stew Peters Show, Analyst David Pyne joins Stew to discuss the elaborate Uniparty plot to lull the American people into supporting a war against Russia that will ultimately lead into World War Three. The acceptance of Communism has destroyed American society. Peymon Hottahedeh joins with Stew to speak out about his thoughts on the matter, and where we move on from here with the IRS constantly trying to rob the American people. Vaccine data trackers are covering up the deaths of children. Albert Benavides comes on to discuss the truth behind attempting to meddle with the VAERS database in an effort to hide the true cost and scale of the jab-induced genocide unleashed on the world. Finally, Dr. Ariyana Love brings on the heat with frightening insights into the possibility that Covid Antibody treatments and the monoclonal antibody treatments could be killing unborn babies in a shocking depopulation agenda. Get Dr. Zelenko's Anti-Shedding Treatment, NOW AVAILABLE FOR KIDS: http://zStackProtocol.com Go Ad-Free, Get Exclusive Content, Become a Premium user: https://redvoicemedia.com/premium Follow Stew on Gab: https://gab.com/RealStewPeters See all of Stew's content at https://StewPeters.TV Watch full episodes here: https://redvoicemedia.net/stew-full-shows Check out Stew's store: http://StewPeters.shop Support our efforts to keep truth alive: https://www.redvoicemedia.com/support-red-voice-media/
TWiV describes the identification of a monoclonal antibody that provides broad protection against a variety of hantaviruses, and development of an oral remdesivir-like antiviral that ameliorates viral disease in mice. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, and Amy Rosenfeld Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monoclonal antibody provides broad hantavirus protection (Sci Transl Med) Prometheus Project (TWiV 578) Oral antiviral related to Remdesivir (Sci Transl Med) Letters read on TWiV 881 Timestamps by Jolene. Thanks! Weekly Picks Dickson – World's tallest wooden building Amy – Virus hunter in the Wuhan market Rich – WorldPop (example) Vincent – Karst Stone Paper Listener Picks Neva – Can we vaccinate against EBV? and Paul Sutter reading a science paper Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
In Virginia, Pennsylvania, and elsewhere, the school mask mandate is the frontline of the fight for freedom. The libs are going to pull back some COVID restrictions this spring- but not all- so they can claim victory in advance of the midterms- and then bring back all the restrictions they want next winter. Fauci is saying that we can't get back to normal until we “control” the virus, which just shows what a maniacal fraud he is. Monoclonal antibodies are shot down by the FDA, and Fauci says they are too risky? Plus Russia hasn't invaded Ukraine- yet. Please subscribe to the podcast! And get more exclusive content from Buck at BuckSexton.com.Find Buck on:Twitter @BuckSexton Facebook @BuckSexton Instagram @BuckSexton Email the Podcast: TeamBuck@IHeartMedia.com Learn more about your ad-choices at https://www.iheartpodcastnetwork.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.
13 reasons not to inject 5-11 year olds. Why does the AMA attack truth tellers. Ted tells a personal story about how he was censored. Why are their so many corrupt physicians? Truckers on strike due to vaccine mandates? What is really going on with the Ukraine? Who was Historian Barry Chamish? Monoclonal antibodies withdrawn by FDA. Why religious exemptions need to be done right. Plus much much more!
A discussion of how my (Rita's) family handled COVID. I run down what we did, but most importantly the thought process behind it. So many people want to know what they can do at home at onset of symptoms and the healthcare system is not obliging. This episode is not medical advice. It is simply information, a story of personal decisions we made in our care, what we did and why. Each individual is responsible for the decisions they make and care they do or do not seek out. Plan ahead, be prepared. https://ritarogersco.com/2022/01/10/early-treatment-prepared-proactive/ https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Alliance-I-MASKplus-Protocol-ENGLISH.pdf https://covid19criticalcare.com/ivermectin-in-covid-19/covid-19-care-providers/ https://covid19criticalcare.com https://vladimirzelenkomd.com/treatment-protocol/ (Monoclonal distribution list) https://protect-public.hhs.gov/pages/therapeutics-distribution (Sulfur article) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372953/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app
© 2020-2025 Ivy Podcast Discovery LLC
